HomeContact UsProduct LinksSite MapSearch   
About BioMarin Products Pipeline Fully Integrated


 


 
   
LATEST NEWS
01/06/09: BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
 
12/09/08: Kuvan Receives Marketing Approval in the European Union
 
11/21/08: BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
 
11/07/08: Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
 
11/05/08: BioMarin to Present at the Credit Suisse Healthcare Conference
 
11/03/08: BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
 
10/28/08: BioMarin Announces Third Quarter 2008 Financial Results
 
10/15/08: BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
 
10/07/08: BioMarin Opens Office in Brisbane to Support Expanding Operations
 
10/07/08: BioMarin to Host Third Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, October 28 at 5:00 p.m. ET (23:00 CET)
 
09/25/08: Kuvan Receives Positive Opinion From CHMP for European Approval
 
07/22/08: BioMarin and Summit plc Sign Worldwide Licensing Agreement for Duchenne Muscular Dystrophy Program
 
07/16/08: Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
 
07/15/08: BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
 
07/01/08: BioMarin to Present at the Collins Stewart Growth Conference
 
06/05/08: BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
 
05/22/08: BioMarin to Host Research and Development Day June 5th
 
05/20/08: BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU



  © 2006 BIOMARIN
  LEGAL NOTICE GLOSSARY
Last updated: 07/24/2008